China's Shaanxi urges API companies to strengthen Antimonopoly Law compliance
MLex Summary: China’s Shaanxi Administration for Market Regulation urged active pharmaceutical ingredient companies to strengthen Antimonopoly compliance across production, sales, purchasing and merger activities, the provincial regulator said in a statement...To view the full article, register now.
Already a subscriber? Click here to view full article